Akebia Therapeutics Files Q1 2025 10-Q
Ticker: AKBA · Form: 10-Q · Filed: May 8, 2025 · CIK: 1517022
| Field | Detail |
|---|---|
| Company | Akebia Therapeutics, Inc. (AKBA) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceutical
Related Tickers: AKBA
TL;DR
Akebia Q1 2025 10-Q filed. Financials updated.
AI Summary
Akebia Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial performance and operations. Key financial data and business segments are presented, reflecting the company's ongoing activities in the pharmaceutical sector.
Why It Matters
This filing provides investors and stakeholders with an update on Akebia Therapeutics' financial health and operational status for the first quarter of 2025, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Akebia Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-05-08 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Akebia Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250508 (date) — Filing date
- 245 FIRST STREET, CAMBRIDGE, MA 02142 (address) — Company's business and mailing address
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 8, 2025.
What is Akebia Therapeutics, Inc.'s primary business classification?
Akebia Therapeutics, Inc. is classified under Pharmaceutical Preparations [2834].
What is the company's principal executive office address?
The company's principal executive office is located at 245 First Street, Cambridge, MA 02142.
What fiscal year end does Akebia Therapeutics observe?
Akebia Therapeutics observes a fiscal year end of December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Akebia Therapeutics, Inc. (AKBA).